Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF), the pharmaceutical company behind iron deficiency treatment Accrufer, has abandoned its target of operating...…
Shield Therapeutics said it will no longer reach profitability this year after failing to achieve the desired effects of taking…
Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical companys agreement to take full...…
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) rose 11% to 4.89p on Thursday after the pharmaceutical company reported sharply narrower…
…
…
…
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings…
Image source: The Motley Fool.DATEThursday, March 12, 2026 at 5 p.m. ETCALL PARTICIPANTSChief Executive Officer — David R. SprengChief Investment…
…
Broker Cavendish says additional US protection strengthens long-term outlook and reiterates buy rating. Shares in Shield Therapeutics PLC (AIM:STX,...…
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) has announced positive results from its Phase 3 pediatric FORTIS trial of ferric maltol (ACCRUFeR). The…
…
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) saw its share price rise 21% following a strong second-quarter trading update. The company reported…
CPP Group (LON: CPP) is selling its business in India for £15.7m, of which £11.8m is payable on completion. The…
Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose as much as 6% on Tuesday morning after the company announced a…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) is gaining momentum. The company, known for its oral iron supplement ACCRUFeR, has reported a…
Shares of Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose in afternoon trading after the company announced a $10 million fundraising commitment…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), a specialist in iron deficiency treatments, said its largest investor, AOP Health International, is backing...…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)’s proposed $10 million equity agreement with AOP Health International Management “should provide some...…
Main Market miner Hamak Gold (LON: HAMA) has sold its 10.1% stake in Vela Technologies (LON: VELA). These are the…
Shares of Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) surged 27% in early trading after strong October sales of its iron deficiency…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)) has reported strong sales of iron deficiency drug ACCRUFeR in October, bolstered by an increase…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) reported strong sales for the third quarter of 2024. It unveiled plans to raise around…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)s share price rose 8% following the announcement of successful phase III trial results for its…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), a UK-based pharmaceutical company specialising in treatments for iron deficiency, announced on Wednesday...…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) interim CEO Anders Lundstrom and CFO Santosh Shanbhag talked with Proactive about the companys impressive...…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) progress was lauded by Peel Hunt in research that followed the speciality pharma groups interims on...…
…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) hailed another strong period of growth as it delivered a more than three-fold increase in…
Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose 7% in early trading following the approval of its drug, Accrufer (ferric maltol), by Health...…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) has announced that Health Canada has approved ACCRUFeR (ferric maltol) as a prescription drug for…
Shield Therapeutics (LON: STX) chief executive Greg Madison is stepping down and non-exec Anders Lundstrom will take over on an…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) shares shot up 47% after it announced a stellar set of second-quarter trading numbers. The update,…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said that chief executive Greg Madison is stepping down from the role by mutual consent to pursue…
Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) were almost 7% higher in afternoon trading after the commercial-stage pharma group fortified…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharma company, has entered into a $5.7 million monetisation agreement with AOP Health...…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharma company, has entered into a $5.7 million monetisation agreement with AOP Health...…
Broker Peel Hunt has kept its rating on Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) under review following news that its Korean…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)s partner, Korea Pharma, has filed a New Drug Application (NDA) for Accrufer with the countrys Ministry of...…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)s full-year results, where the company reported a trebling of total revenues, were consistent with a…
Shield Therapeutics revenues almost trebled in 2023 as sales of its Accrufer/Feraccru iron deficiency treatment ramped up in the US.…
Shield Therapeutics revenues almost trebled in 2023 as sales of its Accrufer/Feraccru iron deficiency treatment ramped up in the US.…
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharmaceutical company, confirmed it is still on course to be cash flow positive…